Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 26, 2012, Pages 10322-10327

  Gilsbach, Bernd K ^a,b   Ho, Franz Y ^c   Vetter, Ingrid R ^b   Van Haastert, Peter J M ^a   Wittinghofer, Alfred ^b   Kortholt, Arjan ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; PROTEIN DAPK1; PROTEIN LEUCINE RICH REPEAT KINASE 1; PROTEIN MFHAS1; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DICTYOSTELIUM DISCOIDEUM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME STRUCTURE; HUMAN; MUTATION; PARKINSON DISEASE; PRIORITY JOURNAL; WILD TYPE;

AMINO ACID SEQUENCE; CRYSTALLOGRAPHY, X-RAY; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PARKINSON DISEASE; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; SEQUENCE HOMOLOGY, AMINO ACID;

DICTYOSTELIUM DISCOIDEUM;

EID: 84862996255     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1203223109     Document Type: Article

References (40)

1. Bosgraaf L, Van Haastert PJ (2003) Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta 1643:5-10. (Pubitemid 37494887)
2. Paisán-Ruíz C, et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44:595-600. (Pubitemid 39531224)
3. Zimprich A, et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601-607. (Pubitemid 39531225)
4. Aasly JO, et al. (2005) Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol 57:762-765. (Pubitemid 40628869)
5. Hernandez DG, et al. (2005) Clinical and positron emission tomography of Parkinson's disease caused by LRRK2. Ann Neurol 57:453-456. (Pubitemid 40343971)
6. Khan NL, et al. (2005) Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: Clinical, pathological, olfactory and functional imaging and genetic data. Brain 128:2786-2796. (Pubitemid 41746633)
7. Cookson MR (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 11:791-797.
8. Gilks WP, et al. (2005) A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365:415-416. (Pubitemid 40179229)
9. Nalls MA, et al.; International Parkinson Disease Genomics Consortium (2011) Imputation of sequence variants for identification of genetic risks for Parkinson's disease: A meta-analysis of genome-wide association studies. Lancet 377:641-649.
10. Cookson MR, Bandmann O (2010) Parkinson's disease: Insights from pathways. Hum Mol Genet 19(R1):R21-R27.
11. Deng J, et al. (2008) Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci USA 105:1499-1504. (Pubitemid 351346543)
12. Gasper R, Meyer S, Gotthardt K, Sirajuddin M, Wittinghofer A (2009) It takes two to tango: Regulation of G proteins by dimerization. Nat Rev Mol Cell Biol 10:423-429.
13. Gotthardt K, Weyand M, Kortholt A, Van Haastert PJ,Wittinghofer A (2008) Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO J 27:2239-2249.
14. Greggio E, et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23:329-341. (Pubitemid 44097032)
15. Luzón-Toro B, Rubio de la Torre E, Delgado A, Pérez-Tur J, Hilfiker S (2007) Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum Mol Genet 16:2031-2039. (Pubitemid 47354886)
16. West AB, et al. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102:16842-16847. (Pubitemid 41688864)
17. Anand VS, Braithwaite SP (2009) LRRK2 in Parkinson's disease: Biochemical functions. FEBS J 276:6428-6435.
18. Greggio E, Cookson MR (2009) Leucine-rich repeat kinase 2 mutations and Parkinson's disease: Three questions. ASN Neuro 1:1.
19. van Egmond WN, et al. (2008) Intramolecular activation mechanism of the Dictyostelium LRRK2 homolog Roco protein GbpC. J Biol Chem 283:30412-30420.
20. van Egmond WN, van Haastert PJ (2010) Characterization of the Roco protein family in Dictyostelium discoideum. Eukaryot Cell 9:751-761.
21. Kicka S, et al. (2011) The LRRK2-related Roco kinase Roco2 is regulated by Rab1A and controls the actin cytoskeleton. Mol Biol Cell 22:2198-2211.
22. Huse M, Kuriyan J (2002) The conformational plasticity of protein kinases. Cell 109: 275-282. (Pubitemid 34606870)
23. Taylor SS, Kornev AP (2011) Protein kinases: Evolution of dynamic regulatory proteins. Trends Biochem Sci 36:65-77.
24. Adams JA (2003) Activation loop phosphorylation and catalysis in protein kinases: Is there functional evidence for the autoinhibitor model? Biochemistry 42:601-607.
25. Kornev AP, Haste NM, Taylor SS, Eyck LF (2006) Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci USA 103:17783-17788. (Pubitemid 44852237)
26. Li X, Moore DJ, Xiong Y, Dawson TM, Dawson VL (2010) Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2. J Biol Chem 285:29569-29576.
27. Greggio E, et al. (2008) The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem 283:16906-16914.
28. Jaleel M, et al. (2007) LRRK2 phosphorylates moesin at threonine-558: Characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405: 307-317. (Pubitemid 47075166)
29. Smith WW, et al. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9:1231-1233. (Pubitemid 44454261)
30. Anand VS, et al. (2009) Investigation of leucine-rich repeat kinase 2 : Enzymological properties and novel assays. FEBS J 276:466-478.
31. Fancelli D, et al. (2005) Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem 48:3080-3084. (Pubitemid 40548120)
32. Ohta E, Kubo M, Obata F (2010) Prevention of intracellular degradation of I2020T mutant LRRK2 restores its protectivity against apoptosis. Biochem Biophys Res Commun 391:242-247.
33. Wan PT, et al.; Cancer Genome Project (2004) Mechanism of activation of the RAFERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-867. (Pubitemid 38410730)
34. Deng X, et al. (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol 7:203-205.
35. Nichols RJ, et al. (2009) Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J 424:47-60.
36. Jacobs M, et al. (2006) The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. J Biol Chem 281:260-268. (Pubitemid 43671185)
37. Breitenlechner C, et al. (2003) Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: Structural basis of selectivity. Structure 11:1595-1607. (Pubitemid 37510358)
38. Kabsch W (2010) XDS. Acta Crystallogr D Biol Crystallogr 66:125-132.
39. Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486-501.
40. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53:240-255. (Pubitemid 27235885)